August 18, 2008 – Maximus, a business unit of leading infusion therapy firm Medegen Inc., said today it entered into a marketing agreement with C.R. Bard, with Medegen’s MaxPlus Clear needleless access connector now included in peripherally inserted central catheter (PICC) kits sold by Bard Access Systems.
The agreement reportedly provides the extra benefits of the MaxPlus Clear product to users of Bard PowerPICC SOLO, the newly launched PICC designed to provide the efficiency of power injection for contrast enhanced CT scans and PICC therapy combined with the simplicity of saline care and maintenance through its valve technology.
The MaxPlus Clear Needleless Access Device is the first and only positive displacement connector that features complete visualization of the fluid path, which is reportedly shown to enhance patient care, leading to lower bloodstream infection and occlusion rates.
The MaxPlus Clear Needleless Access Device will be packaged with all Bard PICC catheters and is also available directly from Maximus, a division of Medegen, as a sterile, pouched product.
For more information: www.medegen.com
July 25, 2024 
